Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease
about
Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical ImplicationsStriatal cholinergic interneuron regulation and circuit effectsDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genesDopamine agonists in Parkinson's diseaseInitial medication in patients of newly diagnosed Parkinson's disease in TaiwanBax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's diseaseL-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa historyAn update on the diagnosis and treatment of Parkinson disease"Cueing" for Levodopa-Induced Dyskinesias in Parkinson's DiseaseReview of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Treatment of early Parkinson's disease.Brittle Dyskinesia Following STN but not GPi Deep Brain Stimulation.Neuroprotective Role of Atractylenolide-I in an In Vitro and In Vivo Model of Parkinson's DiseaseToxin-induced models of Parkinson's disease.Reliability of measurements obtained with the Timed "Up & Go" test in people with Parkinson disease.Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats.Continuous drug delivery in Parkinson's disease.Improving symptom control in early Parkinson's diseaseRevisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine AgonistDrug selection and timing of initiation of treatment in early Parkinson's disease.Present and future drug treatment for Parkinson's disease.Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease.Levodopa in the treatment of Parkinson's disease: current controversies.Clinical aspects and management of levodopa-induced dyskinesia.Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson diseaseCognitive impairment in Parkinson's disease.Parkinson's disease management strategies.D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesiaTreatment of Parkinson's disease in the advanced stage.Perturbation of transcription factor Nur77 expression mediated by myocyte enhancer factor 2D (MEF2D) regulates dopaminergic neuron loss in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).Drug treatment of Parkinson's diseaseCommunity and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.Initiation of Parkinson's disease treatment.A comprehensive model of health-related quality of life in Parkinson's disease.Levodopa-induced dyskinesias and their management.How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?How should we treat a patient with early Parkinson's disease?
P2860
Q26752602-8453D214-7668-4AB5-8382-BA997F7F01BAQ26863113-F8C88D71-B61A-4FC1-885B-E5A1E47C8806Q27021464-3AC5502A-0F43-4DC7-B5E1-24E7F885F9FFQ28088705-0472046E-4536-4037-A224-BCA7AF0B61C8Q28276692-0BBD9873-D36C-4DB1-8A0E-66971F34FB02Q28542989-225F43C9-8694-4491-89D8-BF93AC292672Q28594269-2B69160F-7DEA-4958-9BB7-53D9CFF41DCAQ28602694-26C5333E-D41C-40DF-80BA-2ABF24FF945CQ30243899-203ABD64-4F22-48EC-AD60-0CD5A24E4633Q30366041-EF71A220-D3C6-4E81-B973-2C20D2B2A990Q33260250-D702261D-38B4-4179-B2FE-BC0879208881Q33714133-98C5B37F-3DC6-44CB-923B-E2053671BA43Q33728971-D18A1D45-0149-422D-80E3-F7F4DA246C70Q33749270-8286DEA2-0C78-4FE8-B5C8-82949B32C753Q33844749-CFCFB2E8-59F6-4FA2-8521-09D82238067DQ33933237-150D91F3-C7C7-4F52-94CC-1980023D9EDBQ34279877-DFAD4434-E1DE-4327-9477-23E04EEE734EQ34390800-FE8C3A43-544B-4AE5-BE88-236431078E6DQ34409267-EA043550-BD0C-4F7B-ACCF-8AAD0119100DQ34504316-0CC5021C-5FAC-4421-A19B-CA07700A7BDBQ34602815-7CE59FF0-8807-4669-A343-D02BB9483013Q35484805-B1663F64-8445-4E78-AE96-5BF472DC94CDQ35781883-A699155D-F9EF-44FA-8064-A85514C3507FQ35889917-0716016A-5EC4-4915-B13B-17CDCB491FC4Q36022700-F1129460-6BC3-42A8-83C1-CE1B4F6CA18EQ36167615-94C9B108-78CE-4920-AE5E-027BBB9931FCQ36226772-4125A56B-F659-48C2-B0E1-7A50F346093CQ36390875-7B98173D-690D-4B85-9D4F-3092A1E5D836Q36521275-D2C94CBF-8801-4AAA-84AA-557068E360E0Q36725292-C1FD717D-73A3-4E9E-A033-E6B48DC52F4AQ36850316-B75D9BCC-5C12-479F-890C-8B7D744D3149Q36902632-1F81EE09-653E-4637-B492-D434C5CF313EQ36911874-07E27DB9-3FF8-4F07-A43D-57BE5F36A3A7Q37016310-527CF707-FA90-4AC8-9AA9-0A238FC01619Q37264446-C01BC967-E84B-4959-BB2F-4C800F5D2AC0Q37267316-2F555AF5-2683-4B92-90EA-17419691662BQ37280767-77871E7D-D38D-4515-809B-A462B10146DBQ37280804-5B2F772B-6AA4-495D-A1AC-9384684EF08BQ37363909-356A8C2C-E61D-491D-84B4-68DC2B9BCDC4Q37775098-39197780-7630-41C3-88E9-2E52E0DA95EE
P2860
Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease
description
1991 nî lūn-bûn
@nan
1991 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Early development of levodopa- ...... oung-onset Parkinson's disease
@ast
Early development of levodopa- ...... oung-onset Parkinson's disease
@en
Early development of levodopa- ...... oung-onset Parkinson's disease
@nl
type
label
Early development of levodopa- ...... oung-onset Parkinson's disease
@ast
Early development of levodopa- ...... oung-onset Parkinson's disease
@en
Early development of levodopa- ...... oung-onset Parkinson's disease
@nl
prefLabel
Early development of levodopa- ...... oung-onset Parkinson's disease
@ast
Early development of levodopa- ...... oung-onset Parkinson's disease
@en
Early development of levodopa- ...... oung-onset Parkinson's disease
@nl
P2093
P921
P3181
P1433
P1476
Early development of levodopa- ...... oung-onset Parkinson's disease
@en
P2093
P3181
P356
10.1212/WNL.41.2_PART_1.202
P407
P433
P577
1991-02-01T00:00:00Z